로딩 중…
지수 로딩 중…
Humacyte, Inc.
HUMA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$0.69+5.49%
2026-08-03
Financials
Valuation Metrics
Humacyte, Inc.'s Market Cap is $153M. At end of 2025 it was $152M. Ranked #3057 of 3,112 in US market (top 98%), #1400 of 1,445 on NASDAQ (top 97%), #263 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $153M | US#3,057/3,112 Sec#263/269 |
| Revenue | $2M | US#2,953/3,112 Sec#195/269 |
| Net Income | $-98M | US—/3,112 Sec—/269 |
| Total Assets | $111M | US#3,032/3,112 Sec#264/269 |
| Net Assets | $12M | US#2,992/3,112 Sec#259/269 |
| Value | ||
| P/B | 13.17x | US#2,700/3,112 Sec#216/269 |
| P/S | 75.91x | US#2,898/3,112 Sec#176/269 |
| FCF Yield | -66.90% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROA | -88.27% | US#3,039/3,112 Sec#260/269 |
| Op. Margin | -5649.21% | US#2,953/3,112 Sec#193/269 |
| Revenue Growth | -4.26% | US#2,480/3,112 Sec#135/269 |
| Earnings Growth | -145.02% | US#2,164/3,112 Sec#72/269 |
| Financial Health | ||
| Debt Ratio | 851.11% | US#2,688/3,112 Sec#239/269 |
| Total Debt | $66M | US#2,488/3,112 Sec#141/269 |
| FCF | $-102M | US#2,591/3,112 Sec#153/269 |
| Cash | $49M | US#2,598/3,112 Sec#230/269 |
| Current Ratio | 3.93x | US#600/3,112 Sec#169/269 |
| Performance | ||
| 1Y Return | -69.77% | US#3,086/3,112 Sec#263/269 |
| 1M Return | -2.92% | US#2,013/3,112 Sec#102/269 |
| From 52W High | -75.03% | US#3,059/3,112 Sec#260/269 |
| 1Y MDD | -79.26% | US#3,041/3,112 Sec#260/269 |
| Trading | ||
| Volume | 3,211,270 shares | US#587/3,112 Sec#48/269 |
| Trading Value | $2M | US#2,900/3,112 Sec#242/269 |
| Per Share | ||
| EPS | $-0.10 | US—/3,112 Sec—/269 |